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despite great public interest and desperate need, progress toward a viable human immun-
odeficiency virus (HIV†) vaccine remains incredibly slow. Since Merck began its HIV vac-
cine research in 1985, the pharmaceutical company has yet to produce a vaccine capable
of passing Phase II testing. Merck laboratories President Peter S. Kim recently delivered a
speech at Yale university that detailed his company’s previous attempts to create an HIV
vaccine and outlined a possible strategy for the future. by Kim’s own admission, Merck will
not produce a viable vaccine in the near future. However, the speech served as an impor-
tant endorsement for HIV vaccine development from a highly respected leader in the phar-
maceutical industry, which, historically, has produced drugs aimed at management rather
than prevention.
Audience  members  may  have  been
scratching  their  heads.  Not  because  the
technical jargon and cutting-edge scientific
developments recounted at the Yale School
of Medicine Bicentennial Symposium were
too complex, but because one of the event’s
most intriguing presenters seemed to focus
mainly on his company’s series of failures. 
When Dr. Peter S. Kim, President of
Merck Laboratories, chose to address the
topic of HIV vaccine development, he must
have known more than half of his time
would be spent rehashing the pharmaceuti-
cal giant’s unsuccessful ventures. But de-
spite the lack of an HIV vaccine, the talk
still represented a small victory for propo-
nents of HIV vaccine development who
may be frustrated by the focus of current
pharmaceuticals on disease management
rather than infection prevention. The sub-
ject matter carries additional weight con-
sidering  the  source.  Pharmaceutical
companies profit most easily from long-
term treatments directed toward economi-
cally  stable  markets.  In  spite  of  this,
Merck’s  president  chose  to  champion  a
vaccine that represents the most cost-effec-
tive, and least profitable, treatment of a dis-
ease that mainly affects the world’s poorest
countries. 
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†Abbreviations: HIV, human immunodeficiency virus.“I  believe  this  is  the  largest  public
health issue that science needs to address,”
Kim said.
Why then, after such a strong endorse-
ment and more than 25 years of research,
has Merck failed to produce a viable HIV
vaccine? “It’s not for lack of trying,” Kim
said. “Coming up with a vaccine for HIV
has proven to be very difficult.”
Merck began research on an HIV vaccine
in 1985 and has discovered a variety of dead
ends. Researchers quickly found that using
killed versions of HIV did not work. Merck
also tried a humoral approach, attempting to
persuade  human  antibodies  to  disable  the
virus. This tactic also initially failed.
A more promising solution seemed to
present itself in the cell-mediated strategy.
If one cannot prevent HIV from entering the
body, Merck researchers thought, why not
prime the body’s cytotoxic T cells to recog-
nize and destroy any cell that has been in-
fected with HIV? It seemed like a massive
breakthrough when Merck scientists elicited
this very response in monkeys using the new
MRKAd5 vaccine. The vaccine appeared to
reduce the peak and baseline viral loads in
HIV-infected monkeys. Better yet, the vac-
cine even produced a durable cytotoxic re-
sponse in infected humans.
Problems arose when the vaccine moved
into Phase II human testing. A larger study,
called  the  STEP  study,  began  in  2004  to
measure the protective quality of the vaccine
[1]. The goal of this study was not just to
lower viral counts but to prevent initial infec-
tion in healthy subjects. The result was an
utter failure. Not only did the vaccine fail to
provide protection against HIV, but more vac-
cinated subjects became infected than the un-
vaccinated controls [1]. The study was halted
in 2007, and the scientific community was
stunned. “I think it sets a solid framework for
what doesn’t work,” Kim said.
The failure represented a major setback
for HIV vaccine development and the over-
all campaign against HIV and AIDS. 
Since the disappointing results of the
STEP study, Merck has shifted its attention
back to a humoral-based vaccine. The goal of
this strategy is to prevent the entry of HIV
into cells by blocking the fusion of viral and
host cell membranes [2]. Merck researchers
hope to accomplish this by forcing antibodies
to target the transient structure the virus uses
to enter cells. This structure, known as the
hairpin intermediate, has been targeted by
peptide inhibitors in previous studies [2]. This
plan, however, presents its own challenge:
Since the target structure exists transiently,
scientists must engineer a stable proxy to act
as an immunogen and elicit an antibody re-
sponse. That goal remains elusive. 
While he is optimistic about the re-
newed emphasis on a humoral approach to
the vaccine, Kim said, the medical com-
munity will have to combat HIV without
the relief of a vaccine in the near future. 
“My gut feeling is we still have a long
way to go,” Kim said. “And I don’t mean
‘we’ as in Merck. I mean ‘we’ as a scien-
tific community.” 
In the meantime, Kim’s presentation
on HIV vaccine development offers impor-
tant insight for the discussion of an HIV
vaccine and its role in combating the HIV
epidemic. It is vital that high-profile cor-
porations and industry leaders continue to
place an emphasis on important health is-
sues that do not necessarily represent the
greatest opportunity for profit, but reflect
the most desperate needs of the global pop-
ulation.
By including Kim’s presentation in its
Bicentennial Symposium, Yale School of
Medicine has demonstrated a commitment
to issues that exist not only in test tubes and
sterile laboratories, but in homes and com-
munities around the world. While we are
far from vaccine-based eradication of HIV,
symposium  participants,  as  well  as  the
larger medical community, should appreci-
ate the continued discussion of this topic by
industrial and academic leaders.
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